Aktis Oncology (NASDAQ:AKTS) Hits New 52-Week High – Should You Buy?

Aktis Oncology (NASDAQ:AKTS) hit a new 52-week high during trading on Wednesday . The stock traded as high as $34.19 and last traded at $32.3590, with a volume of 1211861 shares traded. The stock had previously closed at $30.11.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. HC Wainwright increased their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. William Blair began coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target for the company. Finally, Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Up 7.5%

The stock’s fifty day simple moving average is $21.37.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million during the quarter. On average, research analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.